About us
Pepscan Therapeutics is a biopharmaceutical company, successfully tackling the challenges of protein mimicry for the development of novel therapeutic options for a/o cancer and immunological diseases.
Many proteins exert their biological activity through relatively small regions of their folded surfaces. The challenge is to mimic these bioactive surfaces by much smaller peptides. Pepscan’s unique technology platform addresses this issue via the design and synthesis of conformationally constrained peptides with a well-defined 3D spatial structure resembling the native functional protein surface.
Pepscan’s high throughput CLIPS protein mimicking technology platform covers fast screening and efficient synthesis of conformationally constrained peptides, which opens up new avenues for peptide drug discovery. Pepscan’s protein mimicry capabilities have also led to a truly innovative way to unlock the full potential of antibodies against cell membrane integrated receptor targets (such as GPCRs and ion channels).
Pepscan Therapeutics applies its proprietary technology platform for the discovery and development of improved therapeutic peptides and monoclonal antibodies against intractable targets like GPCR's
Besides a pipeline of proprietary therapeutic peptides and anti-GPCR monoclonal antibodies, Pepscan has various ongoing collaborations with leading pharmaceutical companies to develop novel therapeutics based on its proprietary CLIPS technology. The value of Pepscan’s platform has been recognized by strategic partners, as demonstrated by a recent series of R&D collaborations with pharma and biotech companies both in the US and the EU.
Pepscan Therapeutics is a subsidiary of Pepscan Holding NV, a privately held company based in Lelystad, The Netherlands. Founded in 2000, Pepscan currently employs about 35 people.